Exp Clin Endocrinol Diabetes 2000; Vol. 108(2): 142-145
DOI: 10.1055/s-2000-5809
Case Report

© Johann Ambrosius Barth

Melatonin hypersecretion in male patients with adult-onset idiopathic hypogonadotropic hypogonadism

R. Luboshitzky 1 , Z. Shen-Orr 2 , A. Ishai 1 , P. Lavie 3
  • 1 The Endocrine Institute, Haemek Medical Center, Afula
  • 2 The Endocrine Laboratory Rambam Medical Center, Haifa
  • 3 Sleep Laboratory, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Summary:

Increased melatonin secretion observed in male patients with congenital isolated hypogonadotropic hypogonadism and its normalization during testosterone treatment had suggested that melatonin and the reproductive hormones are inter-related. Since these patients have a congenital form of hypogonadism, it is likely that hypermelatoninemia is the consequence of hypogonadism. To further study the relations between the pineal and the reproductive axis in humans, we evaluated melatonin secretion in two men (aged 35 and 50 yrs.) with acquired adult-onset hypogonadotropic hypogonadism. The diagnosis was based on the findings of normal testicular volume, azoospermia, low serum testos-terone, normal LH and FSH levels, but apulsatile LH secretion, and intact anterior pituitary hormones secretion, normal findings on skull radiographic imaging, prior sexual maturation and paternity. Melatonin secretion was assessed as urinary 24 h 6-sulphatoxymelatonin excretion (aMT6s) prior to and during the administration of 250 mg testosterone enanthate per month for 4 months. Pretreatment melatonin production was markedly increased in both patients: 427-915 ng/kg/24 h vs. 204 ± 81 [mean ± SD] in 16 age-matched male controls. During testosterone treatment, aMT6s levels were normalized in one patient (range: 81-287 ng/kg/24 h) and remained elevated in the other patient (range: 830-1280 ng/kg/24 h).

These data indicate that male patients with acquired GnRH deficiency have increased melatonin secretion. Melatonin hypersecretion in these patients may reflect a functional association.

References

  • 1 Berga S L, Mortola J F, Yen S SC. Amplification of nocturnal melatonin secretion in women with functional hypothalamic amenorrhea.  J Clin Endocrinol Metab. 66 242-244 1988; 
  • 2 Bistrian B R, Blackburn G L, Shermann M. Therapeutic index of nutritional depletion in hospitalized patients.  Surg Gynecol Obstet. 141 512-518 1975; 
  • 3 Bojkowski C J, Arendt J. Factors influencing urinary 6-sulphatoxymelatonin - a major melatonin metabolite - in normal human subjects.  Clin Endocrinol. 33 435-444 1990; 
  • 4 Brzezinski A, Lynch J HJ, Seibel M M, Deng M H, Dader T M, Wurtman R J. The circadian rhythm of plasma melatonin during the normal menstrual cycle and in amenorrheic women.  J Clin Endocrinol Metab. 66 891-895 1988; 
  • 5 Comments J, Willig R. No effect of ethinylestradial treatment on melatonin secretion in healthy pubertal girls.  Experim Clin Endocrinol. 103 52-57 1995; 
  • 6 Delfs T M, Baars S, Fock C, Schumacher D, Olcese J, Zimmerman R C. Sex steroids do not alter melatonin secretion in the human.  Human Reprod. 9 49-54 1994; 
  • 7 Kadva A, Djahanbakhch O, Monson J, Di W L, Silman R. Elevated nocturnal melatonin is a consequence of gonadotropin-releasing hormone deficiency in women with hypothalamic amenorrhea.  J Clin Endocrinol Metab. 83 3653-3662 1998; 
  • 8 Klante G, Brinschwitz T, Secci K, Wollnik F, Steinlechner S. Creatinine is an appropriate reference for urinary sulphatoxymelatonin of laboratory animals and humans.  J Pineal Res. 23 191-197 1997; 
  • 9 Laughlin G A, Loucks A B, Yen S SC. Marked augmentation of nocturnal melatonin secretion in amenorrheic athletes but not in cycling athletes, unaltered by opioidergic or dopaminergic blockade.  J Clin Endocrinol Metab. 73 1321-1326 1991; 
  • 10 Leibenluft E, Schmidt P J, Turner E H, Danaceau M A, Ashman S B, Wehr T A, Rubinow D R. Effects of Leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin and prolactin secretion in men.  J Clin Endocrinol Metab. 82 3203-3207 1997; 
  • 11 Luboshitzky R, Lavi S, Thuma I, Lavie P. Increased nocturnal melatonin secretion in male patients with hypogonadotropic hypogonadism and delayed puberty.  J Clin Endocrinol Metab. 80 2144-2148 1995; 
  • 12 Luboshitzky R, Lavi S, Thuma I, Lavie P. Testosterone treatment alters melatonin concentrations in male patients with gonadotropin-releasing hormone deficiency.  J Clin Endocrinol Metab. 81 770-774 1996; 
  • 13 Nachtigal L B, Boepple P A, Pralong F P, Crowley W F. Adult-onset idiopathic hypogonadotropic hypogonadism - A treatable form of male infertility.  N Engl J Med. 336 410-415 1997; 
  • 14 Ozata M, Bulur M, Bingal N, Beyhan Z, Corakci A, Bolu F, Gundogan M A. Daytime plasma melatonin levels in male hypogonadism.  J Clin Endocrinol Metab. 81 1877-1881 1996; 
  • 15 Rajmil O, Puig-Domingo M, Tortosa E, Viader M, Patterson A G, Schwarzstein D, DeLeiva A. Melatonin concentrations before and during testosterone replacement in primary hypogonadic men.  Europ J Endocrinol. 137 48-52 1997; 
  • 16 Skene D J, Vivien-Roels B, Sparks D L, Hunsaker J C, Pevet P, Ravid D, Swaab D F. Daily variation in the concentration of melatonin and 5-methyoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease.  Brain Res. 528 170 1990; 
  • 17 Van Cauter E. Estimating false-positive and false-negative errors in analysis of hormonal pulsatility.  Am J Physiol. 264 E786-E794 1988; 
  • 18 Waldhauser F, Boepple P A, Schemper M, Mansfield M J, Crowley W F. Serum melatonin in central precocious puberty in lower than in age-matched prepubertal children.  J Clin Endocrinol Metab. 73 793-796 1991; 
  • 19 Walker A B, English J, Arendt J, MacFarlane I A. Hypogonadotropic hypogonadism and primary amenorrhea associated with increased melatonin secretion from a cystic pineal lesion.  Clin Endocrinol. 45 353-356 1996; 

1 Values are the mean ± SD in controls and range in patients. * Testicular volume: Values are the mean of right and left testicular columes. BMI: Body Mass Index

2 Values are the mean of four urine collections in each patient before and during testosterone (T) treatment. In brackets: the range of aMT6s values. * Mean ± SD in controls

Prof. R. Luboshitzky

Endocrine Institute

Haemek Medical Center

Afula 18101, Israel

Phone: +9 72-6-6 52 43 54

Fax: +9 72-6-6 52 55 53

Email: gay@tx.technion.ac.il

    >